Lower inflation means less top-line growth from price hikes, and sales volume is under pressure as consumers are more selective.
Investing.com -- As signs emerge that demand for GLP-1 drugs is stronger than expected, many are fearing the worst for packaged-food companies, but Bernstein believes that some companies are likely to fare better than others as patients on these weight-loss drugs shift appetite in favor of more protein-based foods.
CPB's focus on innovation, portfolio reshaping and maintaining affordability positions it well for growth. Yet, cost inflation and Snacks unit hurdles remain.